We are constantly challenging ourselves to find ways to reduce the daily physical, emotional and medical burden that #asthma and #COPD exerts on those affected. We look beyond the visible symptoms to what is happening within the lungs. With an eye on the longer-term impact these conditions can have on a patient’s future, we aim to achieve optimal symptom control, but also target the underlying drivers to prevent exacerbations (attacks) that can lead to cumulative lung damage and disease progression. Discover more about how we’re working to prevent disease progression: https://gsk.to/3K2ZRrX #ATS2024
About us
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- Website
-
http://www.gsk.com
External link for GSK
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Brentford, Middlesex
- Type
- Public Company
- Specialties
- Pharmaceutical products and Vaccines
Locations
Employees at GSK
Updates
-
One in five of those who survive Invasive Meningococcal Disease (IMD) continue to live with life-altering physical and psychological consequences. At GSK, we are committed to preventing infectious diseases. We are proud to be at #ESPID2024 next week where we will focus on our ambition to reduce the impact of IMD. Learn more about the full impact of meningitis through Kate’s experience…https://gsk.to/3K7WBvq
‘Teenagers may feel invincible – but we’re at high risk’: what you need to know about meningitis
gsk.com
-
One the first day of #ATS2024 Kaivan Khavandi, Senior Vice President of Respiratory and Immunology R&D shares his thoughts on how we're determined to apply our expertise to deliver ambitious treatment goals for patients and redefine the future of #respiratory medicine.
-
According to the World Health Organization, #antimicrobialresistance ranks as one of the top 10 threats to global public health. It’s critical that we maintain momentum in tackling this global crisis, but no one person or organisation can do it alone. That’s why we’re excited to share that we will be a founding partner of the global Fleming Initiative. Hear from our CEO, Emma Walmsley, and Lord Darzi, Chair of the Fleming Initiative as they discuss our partnership and how we’re investing in innovation to take a multi-faceted approach to get ahead of #AMR, together: https://gsk.to/3Kp9FwV
-
We are proud that we will be the first founding partner of the global Fleming Initiative – a new global network of scientific, technology, clinical, policy, and public engagement expertise to develop innovative #antimicrobialresistance interventions. According to the World Health Organization, #AMR ranks as one of the top 10 threats to global public health. It is projected to cause 10 million deaths annually by 2050, without effective action. At GSK, we are at the forefront of AMR-relevant research and development and continue to invest in vital partnerships to deliver solutions for this critical issue. Find out more: https://gsk.to/3WDs4xb #AheadTogether
-
Is it time for people with #SevereAsthma to ask if more can be achieved from their care? This #ATS2024, hear more about our focus on R&D and how we're aspiring to achieve more for severe asthma patients. We’ll be presenting further data on our research to drive the next generation standard of care and how clinical remission (12+ months with no exacerbations, freedom from oral corticosteroid use, stabilised lung function and control of symptoms) is now a possibility for people with severe asthma. But in the meantime, find out more about what clinical remission means for #SevereAsthma patients. https://gsk.to/3wyyAun #AheadTogether
https://gsk.to/3JW8Jjg
gsk.com
-
We’re advancing the frontiers of respiratory medicine by aiming to make a difference for patients beyond just symptom control. We are working to: - Protect people from infections and the associated complications, - Prevent deterioration, exacerbations, lung damage and disease progression, - Treat daily symptoms to provide optimal relief and make clinical remission a reality for as many people as possible with severe asthma. Find out more 👇 https://gsk.to/44Hltnp #ATS2024
-
An estimated 5 million people worldwide are living with #lupus – a chronic autoimmune disease that can lead to permanent damage of major organs, including the skin, heart, or kidneys. People living with lupus can experience more severe disease flares and faster disease progression if their condition goes unmanaged and if intervention isn’t timely. This #WorldLupusDay, help shine a light on the lupus community, and learn about the importance of talking with your doctor about living with lupus so you don’t have to face these challenges alone. Learn more: https://bit.ly/3PZpAFp #MakeLupusVisible #LupusAwareness
-
This World Ovarian Cancer Day, we stand in solidarity with the thousands of women who are diagnosed with this disease each year. We remain committed to getting ahead of ovarian cancer and exploring the science behind developing new treatment options for this community. Test your knowledge of ovarian cancer with this poll: #WOCD24 #NoWomanLeftBehind
This content isn’t available here
Access this content and more in the LinkedIn app
-
We need to listen to the people who experience the impact of #asthma every day. Not just on #WorldAsthmaDay. That’s why we’ve listened to Joelle’s experience living with #SevereAsthma, which inspires us in our everyday commitment to help as many people as possible to achieve clinical remission and be free from exacerbations, daily symptoms and the need for oral-corticosteroids. Learn more about the goal of clinical remission in severe asthma: https://gsk.to/3y4MJQB